Non-peptide, once-per-day oral orforglipron to compete with established peptide-based, injectable GLP-1 receptor agonists. Nauck MA, Horowitz M. Lancet 2023;402:429-431.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Nauck MA, Horowitz M. Non-peptide, once-per-day oral orforglipron to compete with established peptide-based, injectable GLP-1 receptor agonists. Lancet 2023;402:429-431.
PMID: 37369233